{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:49Z","timestamp":1787030749443,"version":"build-2736575974"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["666881"],"award-info":[{"award-number":["666881"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CS\/15\/5\/31475"],"award-info":[{"award-number":["CS\/15\/5\/31475"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017506","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","award":["AS-PG-14\u2013033"],"award-info":[{"award-number":["AS-PG-14\u2013033"]}],"id":[{"id":"10.13039\/501100017506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["16\/05 CVD"],"award-info":[{"award-number":["16\/05 CVD"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2022,8,16]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cerebral small vessel disease (SVD) causes lacunar strokes (25% of all ischaemic strokes), physical frailty and cognitive impairment and vascular and mixed dementia. There is no specific treatment to prevent progression of SVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The LACunar Intervention Trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibility study assessing cilostazol and isosorbide mononitrate for preventing SVD progression. We aimed to recruit 400 patients with clinically evident lacunar ischaemic stroke and randomised to cilostazol, isosorbide mononitrate, both or neither, in addition to guideline secondary ischaemic stroke prevention, in a partial factorial design. The primary outcome is feasibility of recruitment and adherence to medication; key secondary outcomes include: drug tolerability; recurrent vascular events, cognition and function at 1\u2009year after randomisation; and safety (bleeding, falls, death). Data are number (%) and median (IQR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The trial commenced on 5 February 2018 and ceased recruitment on 31 May 2021 with 363 patients randomised, with the following baseline characteristics: average age 64 (56.0, 72.0) years, female 112 (30.9%), stroke onset to randomisation 79.0 (27.0, 244.0) days, hypertension 267 (73.6%), median blood pressures 143.0 (130.0, 157.0)\/83.0 (75.0, 90.0) mm Hg, current smokers 67 (18.5%), educationally achieved end of school examinations (A-level) or higher 118 (32.5%), modified Rankin scale 1.0 (0.0, 1.0), National Institutes Health stroke scale 1.0 (1.4), Montreal Cognitive Assessment 26.0 (23.0, 28.0) and total SVD score on brain imaging 1.0 (0.0, 2.0). This publication summarises the baseline data and presents the statistical analysis plan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The trial is currently in follow-up which will complete on 31 May 2022 with results expected in October 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN14911850\">ISRCTN14911850<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2022-001816","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T10:55:50Z","timestamp":1662116150000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"isrctn14911850","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn14911850","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":false,"given":"Philip M","family":"Bath","sequence":"first","affiliation":[{"name":"Stroke Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Mhlanga","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-1999","authenticated-orcid":false,"given":"Lisa J","family":"Woodhouse","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-3148","authenticated-orcid":false,"given":"Fergus","family":"Doubal","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Oatey","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-6642","authenticated-orcid":false,"given":"Joanna M","family":"Wardlaw","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2025082410513814000_8.2.134.1","doi-asserted-by":"crossref","unstructured":"Wardlaw JM , Smith C , Dichgans M . Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019.doi:10.1016\/S1474-4422(19)30079-1","DOI":"10.1016\/S1474-4422(19)30079-1"},{"key":"2025082410513814000_8.2.134.2","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12466"},{"key":"2025082410513814000_8.2.134.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204133"},{"key":"2025082410513814000_8.2.134.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60852-1"},{"key":"2025082410513814000_8.2.134.5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1042\/CS20160382","article-title":"Hypercholesterolaemia and vascular dementia","volume":"131","author":"Appleton","year":"2017","journal-title":"Clin Sci"},{"key":"2025082410513814000_8.2.134.6","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.11.2.254"},{"key":"2025082410513814000_8.2.134.7","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000149621.95215.ea"},{"key":"2025082410513814000_8.2.134.8","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029454"},{"key":"2025082410513814000_8.2.134.9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9507","article-title":"Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats","volume":"10","author":"Rajani","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025082410513814000_8.2.134.10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15132"},{"key":"2025082410513814000_8.2.134.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.12.016"},{"key":"2025082410513814000_8.2.134.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.02.003"},{"key":"2025082410513814000_8.2.134.13","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007142","article-title":"WMH and long-term outcomes in ischemic stroke: a systematic review and meta-analysis","volume":"92","author":"Georgakis","year":"2019","journal-title":"Neurology"},{"key":"2025082410513814000_8.2.134.14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2018.3122","article-title":"Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis","volume":"76","author":"Debette","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025082410513814000_8.2.134.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319134"},{"key":"2025082410513814000_8.2.134.16","doi-asserted-by":"crossref","first-page":"CXI","DOI":"10.1177\/23969873211012132","article-title":"ESO guideline on covert cerebral small vessel disease","volume":"6","author":"Wardlaw","year":"2021","journal-title":"Eur Stroke J"},{"key":"2025082410513814000_8.2.134.17","doi-asserted-by":"publisher","DOI":"10.1177\/2396987320920110"},{"key":"2025082410513814000_8.2.134.18","doi-asserted-by":"publisher","DOI":"10.1159\/000286342"},{"key":"2025082410513814000_8.2.134.19","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010665"},{"key":"2025082410513814000_8.2.134.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008881"},{"key":"2025082410513814000_8.2.134.21","doi-asserted-by":"publisher","DOI":"10.1177\/1747493017731947"},{"key":"2025082410513814000_8.2.134.22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00723","article-title":"Effects of isosorbide mononitrate and\/or cilostazol on hematological markers, platelet function, and hemodynamics in patients with lacunar ischaemic stroke: safety data from the lacunar Intervention-1 (LACI-1) trial","volume":"10","author":"Appleton","year":"2019","journal-title":"Front Neurol"},{"key":"2025082410513814000_8.2.134.23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eclinm.2019.04.001","article-title":"Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: the lacunar Intervention-1 (LACI-1) trial, a randomised clinical trial","volume":"11","author":"Blair","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2025082410513814000_8.2.134.24","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.034866"},{"key":"2025082410513814000_8.2.134.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18556"},{"key":"2025082410513814000_8.2.134.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04828-8","article-title":"Prospective reporting of statistical analysis plans for randomised controlled trials","volume":"21","author":"Hemming","year":"2020","journal-title":"Trials"},{"key":"2025082410513814000_8.2.134.27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(00)04017-4","article-title":"Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies","volume":"357","author":"MacMahon","year":"2001","journal-title":"The Lancet"},{"key":"2025082410513814000_8.2.134.28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2215-0366(20)30431-4","article-title":"Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis","volume":"8","author":"Clancy","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2025082410513814000_8.2.134.29","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.558809"},{"key":"2025082410513814000_8.2.134.30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.756887"},{"key":"2025082410513814000_8.2.134.31","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002227"},{"key":"2025082410513814000_8.2.134.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000837"}],"updated-by":[{"DOI":"10.1136\/svn-2022-001816corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000}}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2022-001816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:51:50Z","timestamp":1756057910000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2022-001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,25]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/svn-2022-001816"],"URL":"https:\/\/doi.org\/10.1136\/svn-2022-001816","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.31.22275743","asserted-by":"object"}]},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}